Two sets of data from VENUS (VESIcare Efficacy and Safety ...
For Immediate Release
NEWLY PRESENTED DATA ON VESICARE® (solifenacin succinate) SHOW SIGNIFICANT IMPROVEMENTS IN URGENCY FOR PATIENTS WITH OVERACTIVE BLADDER
- VESIcare is the First Overactive Bladder Treatment At An Approved Dose to Show a Statistically Significant Increase In Warning Time Before Urination-
Christchurch, New Zealand – December 1, 2006 – Patients with overactive bladder (OAB) treated with VESIcare® (solifenacin succinate) experienced statistically significant reductions in episodes of urgency (the sudden, compelling need to urinate), according to a new study presented today at the 36th Annual Meeting of the International Continence Society.
A secondary endpoint from this study also presented today demonstrated that patients taking VESIcare experienced a statistically significant increase in warning time – compared with patients taking placebo (31.5 seconds vs. 12.0 seconds median increase, respectively; p ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- symptoms of a stroke anthem
- two sets of data from venus vesicare efficacy and safety
- loudoun county public schools
- maternal poc part 2 michigan
- how to care for a patient with diabetes cnazone
- seizure disorders cnazone
- maternal plan of care part 2 hypertension
- sudden loss of consciousness syncope
- emergency medicine—the differential diagnosis of syncope
- fmcsa medical examiner handbook